scholarly journals Natural Supplements for COVID19—Background, Rationale, and Clinical Trials

2021 ◽  
Vol 26 ◽  
pp. 2515690X2110368
Author(s):  
Melody Hermel ◽  
Megan Sweeney ◽  
Yu-Ming Ni ◽  
Robert Bonakdar ◽  
Douglas Triffon ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Potential Benefit ◽  
Viral Infections ◽  
Scientific Evidence ◽  
Biomedical Literature ◽  
Treatment Modalities ◽  
Controversial Issues ◽  
Effective Prevention ◽  
Prevention And Treatment ◽  
Current Guidelines

Worldwide, the turmoil of the SARS-CoV-2 (COVID-19) pandemic has generated a burst of research efforts in search of effective prevention and treatment modalities. Current recommendations on natural supplements arise from mostly anecdotal evidence in other viral infections and expert opinion, and many clinical trials are ongoing. Here the authors review the evidence and rationale for the use of natural supplements for prevention and treatment of COVID-19, including those with potential benefit and those with potential harms. Specifically, the authors review probiotics, dietary patterns, micronutrients, antioxidants, polyphenols, melatonin, and cannabinoids. Authors critically evaluated and summarized the biomedical literature published in peer-reviewed journals, preprint servers, and current guidelines recommended by expert scientific governing bodies. Ongoing and future trials registered on clinicaltrials.gov were also recorded, appraised, and considered in conjunction with the literature findings. In light of the controversial issues surrounding the manufacturing and marketing of natural supplements and limited scientific evidence available, the authors assessed the available data and present this review to equip clinicians with the necessary information regarding the evidence for and potential harms of usage to promote open discussions with patients who are considering dietary supplements to prevent and treat COVID-19.

scholarly journals Role of Factor Xa Inhibitors in Cancer-Associated Thrombosis: Any New Data?

2011 ◽  
Vol 2011 ◽  
pp. 1-12 ◽  
Author(s):  
Ali Zalpour ◽  
Michael H. Kroll ◽  
Vahid Afshar-Kharghan ◽  
Syed Wamique Yusuf ◽  
Carmen Escalante
Keyword(s):  
Clinical Trials ◽  
Cancer Patients ◽  
Anticoagulation Therapy ◽  
Factor Xa ◽  
Factor Xa Inhibitors ◽  
The Us ◽  
Prevention And Treatment ◽  
Cancer Associated Thrombosis ◽  
Current Guidelines

The association between cancer and venous thromboembolism (VTE) has been well documented in the literature. Prevention and treatment of VTE in cancer patients is imperative. Typically, the mainstay regimen for VTE prevention and treatment has been anticoagulation therapy, unless contraindicated. This therapy consists of unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), factor Xa inhibitor, or vitamin K antagonist (VKA). Current guidelines recommend LMWH over VKA for the treatment of VTE in cancer patients. Factor-specific anticoagulants have been proven safe and effective, and recently factor Xa inhibitors have emerged as a treatment alternative to heparins and VKA. Currently, three factor Xa inhibitors have been identified: fondaparinux (the only one approved so far by the US Food and Drug Administration), idraparinux (in clinical trials), and idrabiotaparinux (in clinical trials). This paper will examine the role of these agents, focusing on fondaparinux, for the prevention and treatment of VTE in cancer patients.

scholarly journals Probiotics against Viral Infections: Current Clinical Trials and Future Perspectives

Immuno ◽  
2021 ◽  
Vol 1 (4) ◽  
pp. 468-498
Author(s):  
Pedro A. Reyes-Castillo ◽  
Raquel González-Vázquez ◽  
Edgar Torres-Maravilla ◽  
Mario Tello ◽  
Luis G. Bermúdez-Humarán ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Viral Infections ◽  
Scientific Evidence ◽  
Intestinal Barrier ◽  
Therapeutic Effects ◽  
Host Immune System ◽  
Major Health Problem ◽  
Human Immunodeficiency Viruses ◽  
Etiological Agents ◽  
Tract Infections

Viral infections represent a major health problem worldwide. Due to the wide variety of etiological agents and their increasing resistance to anti-virals and antibiotics treatments, new strategies for effective therapies need to be developed. Scientific evidence suggests that probiotics may have prophylactic and therapeutic effects in viral diseases. Indeed, these microorganisms interact harmoniously with the intestinal microbiota and protect the integrity of the intestinal barrier as well as modulate the host immune system. Currently, clinical trials with probiotics have been documented in respiratory tract infections, infections caused by human immunodeficiency viruses, herpes, human papillomavirus and hepatic encephalopathy. However, the benefits documented so far are difficult to extrapolate, due to the strain-dependent effect. In addition, the dose of the microorganism used as well as host characteristics are other parameters that should be consider when advocating the use of probiotics to treat viral infections. This review addresses the scientific evidence of the efficacy of probiotics in clinical strains perspective in viral infectious diseases in the last 10 years.

scholarly journals Integrated Medicine for Chemotherapy-Induced Peripheral Neuropathy

2021 ◽  
Vol 22 (17) ◽  
pp. 9257
Author(s):  
Chih-Hung Tsai ◽  
Yuan-Ho Lin ◽  
Yung-Sheng Li ◽  
Trung-Loc Ho ◽  
Le Huynh Hoai Thuong ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Peripheral Neuropathy ◽  
Recent Progress ◽  
Therapeutic Strategy ◽  
Treatment Strategies ◽  
Common Side Effect ◽  
Integrated Medicine ◽  
Effective Prevention ◽  
Effective Strategies ◽  
Prevention And Treatment

Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of typical chemotherapeutics among cancer survivors. Despite the recent progress, the effective prevention and treatment strategies for CIPN remain limited. Better understanding of the pathogenesis of CIPN may provide new niches for developing a new ideal therapeutic strategy. This review summarizes the current understanding of CIPN and current recommendations along with completed/active clinical trials and aims to foster translational research to improve the development of effective strategies for managing CIPN.

scholarly journals Antiviral plant preparation as a topical treatment for respiratory viral infections in adults and children

2021 ◽  
pp. 270-275
Author(s):  
Seda S. Grigoryan ◽  
Tatiana I. Garashchenko
Keyword(s):  
Clinical Trials ◽  
Influenza A ◽  
Respiratory Diseases ◽  
Randomized Clinical Trials ◽  
Viral Infections ◽  
Antiviral Drug ◽  
Root Extract ◽  
Wide Range ◽  
Prevention And Treatment ◽  
Respiratory Viral Infections

On average, of the 57 million (currently more) annual deaths worldwide, more than 25% are directly related to infectious diseases. Of these, more than 90% are epidemics of respiratory viral diseases, including variants of influenza and a new coronavirus infection, as well as HIV/AIDS, gastrointestinal diseases, tuberculosis, malaria, measles, and associated bacterial complications. Of particular importance in the prevention and treatment of respiratory viral infections in at-risk groups is the use of plant preparations notable for their safety, absence of undesirable side effects and well studied in the treatment regimens of airborne diseases. The article focuses on an antiviral drug based on a liquid root extract of South African geranium Pilargonium sidoides (EPs® 7630) that meets these requirements. Antiviral activity of the drug was investigated and established in the model of different strains of influenza virus and other respiratory viral infections in cell cultures MDCK, Vero, A549, L 929 and human embryonic fibroblasts, as well as in vivo in a number of randomized clinical trials in children and adults with acute respiratory infections. In addition, EPs® 7630 has proven antiviral effect on the replication of a wide range of respiratory viruses, including influenza A virus (H1N1, H3N2, H5N1), respiratory syncytial virus (RSV), adenovirus, parainfluenza virus, rhinovirus, coxsackievirus and one of human coronaviruses. A review of randomized multicenter placebo-controlled double-blind clinical trials conducted in different years in different countries on the effectiveness of EPs® 7630 is presented. Taking into account the results of efficacy trials in the prevention and treatment of viral respiratory diseases conducted in different years, EPs® 7630 is deservedly included in international and Russian recommendations. It is preferred as a universal agent for antiviral therapy and prevention of a wide range of respiratory diseases in children and adults.

scholarly journals Cognitive impairment in patients with migraine: causes, principles of effective prevention and treatment

2018 ◽  
Vol 10 (3) ◽  
pp. 141-149
Author(s):  
V. A. Golovacheva ◽  
K. A. Pozhidaev ◽  
A. A. Golovacheva
Keyword(s):  
Clinical Trials ◽  
Cognitive Impairment ◽  
Anxiety Disorder ◽  
White Matter ◽  
Effective Prevention ◽  
Pathogenetic Role ◽  
Brain White Matter ◽  
Prevention And Treatment ◽  
The Brain

Cognitive impairment (CI) is common in patients with migraine; its causes and pathogenesis continue to be discussed. Some authors consider that migraine proper does not lead to decreased cognitive functions, neuroimaging changes in the brain white matter are asymptomatic in migraine; and CI in patients with this condition is caused by comorbidities (depression, anxiety disorder) and/or concurrent cerebrovascular and neurodegenerative diseases. Other authors report the pathogenetic role of migraine in the development of CI and the importance of the frequency of headache attacks and neuroimaging changes in the brain matter in migraine. The paper reviews clinical trials dealing with the prevalence, causes, and pathogenesis of CI in patients with migraine. It sets forth the current principles of prevention and treatment of CI in patients with this condition.

scholarly journals The development of neutralizing antibodies against SARS-CoV-2 and their common features

2020 ◽  
Author(s):  
Liu Daisy Liu ◽  
Chaoyang Lian ◽  
Leng-Siew Yeap ◽  
Fei-Long Meng
Keyword(s):  
Clinical Trials ◽  
Severe Acute Respiratory Syndrome ◽  
Neutralizing Antibodies ◽  
Viral Infections ◽  
Common Features ◽  
Prevention And Treatment ◽  
Antibody Discovery ◽  
The Common ◽  
Antibody Technology ◽  
Neutralizing Epitopes

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide severe coronavirus disease 2019 (COVID-19) pandemic since December 2019. There is a great demand for effective therapies for the prevention and treatment of COVID-19. Developing therapeutic neutralizing antibodies (NAbs), which could block viral infection, issuch a promising approach, as NAbs have been successfully applied to the treatment of other viral infections. The recent advances of antibody technology have greatly accelerated the discovery of SARS-CoV-2 NAbs, and many of which are now actively tested in clinical trials. Here, we review the approaches applied for SARS-CoV-2 NAb development, and discuss the emerging technologies underlining the antibody discovery. We further summarize the common features of these antibodies including the shared neutralizing epitopes and sequence features.

Antibody Therapy for the Control of Viral Diseases: An Update

2019 ◽  
Vol 20 (13) ◽  
pp. 1108-1121 ◽  
Author(s):  
Miriam Dibo ◽  
Eduardo C. Battocchio ◽  
Lucas M. dos Santos Souza ◽  
Matheus D. Veloso da Silva ◽  
Bruna K. Banin-Hirata ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Monoclonal Antibodies ◽  
Viral Antigen ◽  
Viral Infections ◽  
Antibody Therapy ◽  
Therapeutic Strategies ◽  
Viral Diseases ◽  
Specific Antibodies ◽  
The Status ◽  
Epidemiological Impact

The epidemiological impact of viral diseases, combined with the emergence and reemergence of some viruses, and the difficulties in identifying effective therapies, have encouraged several studies to develop new therapeutic strategies for viral infections. In this context, the use of immunotherapy for the treatment of viral diseases is increasing. One of the strategies of immunotherapy is the use of antibodies, particularly the monoclonal antibodies (mAbs) and multi-specific antibodies, which bind directly to the viral antigen and bring about activation of the immune system. With current advancements in science and technology, several such antibodies are being tested, and some are already approved and are undergoing clinical trials. The present work aims to review the status of mAb development for the treatment of viral diseases.

Prevention and Treatment of Diabetic Retinopathy: Evidence from Clinical Trials and Perspectives

2011 ◽  
Vol 7 (3) ◽  
pp. 190-200 ◽  
Author(s):  
Manuela Abbate ◽  
Paolo Cravedi ◽  
Ilian Iliev ◽  
Giuseppe Remuzzi ◽  
Piero Ruggenenti
Keyword(s):  
Clinical Trials ◽  
Diabetic Retinopathy ◽  
Prevention And Treatment

MAPK: A Key Player in the Development and Progression of Stroke

2020 ◽  
Vol 19 (4) ◽  
pp. 248-256
Author(s):  
Yangmin Zheng ◽  
Ziping Han ◽  
Haiping Zhao ◽  
Yumin Luo
Keyword(s):  
Ischemic Stroke ◽  
Signaling Pathway ◽  
Complex Disease ◽  
Therapeutic Targets ◽  
Cell Types ◽  
Mapk Signaling ◽  
Mapk Signaling Pathway ◽  
Effective Prevention ◽  
Prevention And Treatment ◽  
Different Cell Types

Conclusion: Stroke is a complex disease caused by genetic and environmental factors, and its etiological mechanism has not been fully clarified yet, which brings great challenges to its effective prevention and treatment. MAPK signaling pathway regulates gene expression of eukaryotic cells and basic cellular processes such as cell proliferation, differentiation, migration, metabolism and apoptosis, which are considered as therapeutic targets for many diseases. Up to now, mounting evidence has shown that MAPK signaling pathway is involved in the pathogenesis and development of ischemic stroke. However, the upstream kinase and downstream kinase of MAPK signaling pathway are complex and the influencing factors are numerous, the exact role of MAPK signaling pathway in the pathogenesis of ischemic stroke has not been fully elucidated. MAPK signaling molecules in different cell types in the brain respond variously after stroke injury, therefore, the present review article is committed to summarizing the pathological process of different cell types participating in stroke, discussed the mechanism of MAPK participating in stroke. We further elucidated that MAPK signaling pathway molecules can be used as therapeutic targets for stroke, thus promoting the prevention and treatment of stroke.

scholarly journals COVID-19: Role of Nutrition and Supplementation

Nutrients ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 976
Author(s):  
Fiorenzo Moscatelli ◽  
Francesco Sessa ◽  
Anna Valenzano ◽  
Rita Polito ◽  
Vincenzo Monda ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Viral Infections ◽  
Overweight And Obesity ◽  
Shortness Of Breath ◽  
Nutritional Interventions ◽  
The World ◽  
Diet Regimen ◽  
Specific Diet

At the end of 2019, a new coronavirus (COVID-19) appeared on the world scene, which mainly affects the respiratory system, causing pneumonia and multi-organ failure, and, although it starts with common symptoms such as shortness of breath and fever, in about 2–3% of cases it leads to death. Unfortunately, to date, no specific treatments have been found for the cure of this virus and, therefore, it is advisable to implement all possible strategies in order to prevent infection. In this context, it is important to better define the role of all behaviors, in particular nutrition, in order to establish whether these can both prevent infection and improve the outcome of the disease in patients with COVID-19. In the literature, it is widely shown that states of malnutrition, overweight, and obesity negatively affect the immune system, leading to viral infections, and several studies have shown that nutritional interventions can act as immunostimulators, helping to prevent viral infections. Even if several measures, such as the assumption of a specific diet regimen, the use of dietary supplements, and other similar interventions, are promising for the prevention, management, and recovery of COVID-19 patients, it is important to highlight that strong data from randomized clinical trials are needed to support any such assumption. Considering this particular scenario, we present a literature review addressing several important aspects related to diet and SARS-CoV-2 infection, in order to highlight the importance of diet and supplementation in prevention and management of, as well as recovery from COVID-19.

Sign in / Sign up

Export Citation Format

Share Document